Home/TG Therapeutics/Sean A. Power

SA

Sean A. Power

Chief Financial Officer

TG Therapeutics

Therapeutic Areas

Multiple Sclerosis Hematologic Malignancies Autoimmune Diseases

TG Therapeutics Pipeline

Drug	Indication	Phase
BRIUMVI (ublituximab)	Relapsing Forms of Multiple Sclerosis	Approved
Ublituximab	Newly Diagnosed Multiple Sclerosis	Phase 3
TG-1701	B-Cell Malignancies	Phase 1
TG-1801	B-Cell Malignancies	Phase 1

Leadership Team at TG Therapeutics

Michael S. Weiss

Executive Chairman and Chief Executive Officer

Chief Medical Officer

David T. Y. Liu

Head of Business Development and Strategy

Jenna M. Goldberg

General Counsel and Corporate Secretary

View full TG Therapeutics profile